| 2024-03-28 |
财报披露：
美东时间 2024-03-28 盘前发布财报
|
| 2024-02-07 |
详情>>
股本变动：
变动后总股本296.37万股
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-5.3美元,归母净利润-999.5万美元,同比去年增长77.10%
|
| 2023-10-03 |
详情>>
内部人交易：
Coiante Scott M股份增加20000.00股
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-6.85美元,归母净利润-919.7万美元,同比去年增长61.66%
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-5.91美元,归母净利润-539万美元,同比去年增长54.20%
|
| 2023-04-28 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.Elect one (1) director named in the proxy statement accompanying this notice to serve as a Class III director until the 2026 Annual Meeting of Stockholders and until her successor is duly elected and qualified.
2.Conduct a non-binding advisory vote on the 2022 compensation of our named executive officers.
3.Approve the Agile Therapeutics, Inc. 2023 Equity Incentive Plan.
4.Ratify the appointment of Ernst & Young LLP as Agile Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2023.
5.Transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2023-04-11 |
详情>>
拆分方案：
每50.0000合并分成1.0000股
|
| 2023-03-23 |
详情>>
业绩披露：
2022年年报每股收益-1.18美元,归母净利润-2541.2万美元,同比去年增长66.07%
|
| 2023-03-23 |
详情>>
业绩披露：
2020年年报每股收益-24.4美元,归母净利润-5185.3万美元,同比去年增长-178.69%
|
| 2023-02-09 |
股东大会：
将于2023-03-09召开股东大会
会议内容 ▼▲
- 1.An amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Annex A, to, at the discretion of the Board of Directors (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, at a ratio of 1-for-20 to 1-for-50, at any time prior to June 30, 2023 with the exact ratio to be determined within that range at the discretion of the Board (such proposal, the “Reverse Stock Split Proposal”) and included in a public announcement;
2.An adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation of proxies in the event there are not sufficient votes in favor Proposal 1.
|
| 2022-11-07 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.91美元,归母净利润-4365.2万美元,同比去年增长15.30%
|
| 2022-08-11 |
详情>>
业绩披露：
2022年中报每股收益-6.29美元,归母净利润-2398.8万美元,同比去年增长31.00%
|
| 2022-05-12 |
详情>>
业绩披露：
2022年一季报每股收益-3.78美元,归母净利润-1176.9万美元,同比去年增长31.29%
|
| 2022-04-29 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.Elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
2.Conduct a non-binding advisory vote on the 2021 compensation of our named executive officers.
3.Approve an amendment to Agile Therapeutics, Inc.'s Amended and Restated 2014 Incentive Compensation Plan
4.Ratify the appointment of Ernst & Young LLP as Agile Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2022.
5.Transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2022-04-27 |
详情>>
拆分方案：
每40.0000合并分成1.0000股
|
| 2022-03-30 |
详情>>
业绩披露：
2021年年报每股收益-0.77美元,归母净利润-7489.4万美元,同比去年增长-44.44%
|
| 2022-03-28 |
股东大会：
将于2022-04-21召开股东大会
会议内容 ▼▲
- 1.an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-10 and 1-for-40, at any time prior to December 31, 2022, with the exact ratio to be set within that range at the discretion of our Board of Directors (the “Board”), without further approval or authorization of our stockholders;
2.the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.
|
| 2021-12-30 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.57美元,归母净利润-5153.7万美元,同比去年增长-50.55%
|
| 2021-12-02 |
股东大会：
将于2022-01-07召开股东大会
会议内容 ▼▲
- 1.Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 150,000,000 shares to 300,000,000 shares.
2.Approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-23 |
股东大会：
将于2021-06-08召开股东大会
会议内容 ▼▲
- 1.Elect three directors named in the proxy statement accompanying this notice to serve as Class I directors until the 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
2.Conduct a non-binding advisory vote on the 2020 compensation of our named executive officers.
3.Ratify the appointment of Ernst & Young LLP as Agile Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2021.
4.Transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2020-04-24 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- (1)Elect two directors named in the proxy statement accompanying this notice to serve as Class III directors until the 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
(2)Conduct a non-binding advisory vote on the 2019 compensation of our named executive officers.
(3)Conduct a non-binding advisory vote on the frequency of future stockholder votes on the compensation of our named executive officers.
(4)Ratify the appointment of Ernst & Young LLP as Agile Therapeutics, Inc.’s independent registered public accounting firm for the year ending December 31, 2020.
(5)Transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2020-02-13 |
复牌提示：
2020-02-13 10:17:37 停牌，复牌日期 2020-02-13 10:27:37
|
| 2019-04-25 |
股东大会：
将于2019-06-06召开股东大会
会议内容 ▼▲
- 1.To elect two directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting held in 2022 and until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as Agile Therapeutics, Inc.'s independent registered public accounting firm for the year ending December 31, 2019.
3.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2018-04-25 |
股东大会：
将于2018-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three directors named in the proxy statement accompanying this notice to serve as Class I directors until the annual meeting held in 2021 and until their successors are duly elected and qualified.
2.To approve Agile Therapeutics, Inc.'s Amended and Restated 2014 Incentive Compensation Plan.
3.To ratify the appointment of Ernst & Young LLP as Agile Therapeutics, Inc.'s independent registered public accounting firm for the year ending December 31, 2018.
4.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2017-04-24 |
股东大会：
将于2017-06-08召开股东大会
会议内容 ▼▲
- 1.To elect two directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting held in 2019 and until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as Agile Therapeutics, Inc.'s independent registered public accounting firm for the year ending December 31, 2016.
3.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|
| 2016-04-25 |
股东大会：
将于2016-06-08召开股东大会
会议内容 ▼▲
- 1.To elect two directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting held in 2019 and until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as Agile Therapeutics, Inc.'s independent registered public accounting firm for the year ending December 31, 2016.
3.To transact such other business as may properly come before the annual meeting or any adjournment thereof.
|